We would love for you to become a part of our community. Join our Discord to connect with us and other members!

Ticker
AARTIDRUGS.NSE

Price
460.40
Stock movement down
-4.90 (-1.06%)
Company name
Aarti Drugs Limited
Exchange
(NSE
,
Currency
INR
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Market cap
41.57B
Ent value
52.98B
Price/Sales
1.75
Price/Book
3.25
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
27.31
Forward P/E
-
PEG
-
EPS growth
14.40%
1 year return
-7.68%
3 year return
-6.93%
5 year return
28.21%
10 year return
18.12%
Last updated: 2025-01-02

DIVIDENDS

AARTIDRUGS.NSE does not pay dividends or no data was received

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E27.31
Price to OCF164.19
Price to FCF164.19
Price to EBITDA57.89
EV to EBITDA73.77

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales1.75
Price to Book3.25
EV to Sales2.23

FINANCIALS

Per share

Loading...
Per share data
Current share count91.27M
EPS (TTM)16.65
FCF per share (TTM)2.77

Income statement

Loading...
Income statement data
Revenue (TTM)23.80B
Gross profit (TTM)7.04B
Operating income (TTM)2.36B
Net income (TTM)1.52B
EPS (TTM)16.65
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)29.58%
Operating margin (TTM)9.93%
Profit margin (TTM)6.40%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash113.40M
Net receivables6.83B
Total current assets12.56B
Goodwill0.00
Intangible assets22.40M
Property, plant and equipment0.00
Total assets24.30B
Accounts payable3.98B
Short/Current long term debt5.90B
Total current liabilities7.81B
Total liabilities11.52B
Shareholder's equity12.78B
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)253.20M
Capital expenditures (TTM)0.00
Free cash flow (TTM)253.20M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity11.91%
Return on Assets6.27%
Return on Invested Capital9.64%
Cash Return on Invested Capital1.60%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open462.55
Daily high464.75
Daily low454.00
Daily Volume97K
All-time high1011.85
1y analyst estimate555.00
Beta0.83
EPS (TTM)16.65
Dividend per share-
Ex-div date6 Feb 2024
Next earnings date22 Jan 2025

Downside potential

Loading...
Downside potential data
AARTIDRUGS.NSES&P500
Current price drop from All-time high-54.50%-3.58%
Highest price drop-81.17%-56.47%
Date of highest drop3 Mar 20099 Mar 2009
Avg drop from high-36.51%-11.12%
Avg time to new high40 days12 days
Max time to new high1957 days1805 days
COMPANY DETAILS
AARTIDRUGS.NSE (Aarti Drugs Limited) company logo
Marketcap
41.57B
Marketcap category
Large-cap
Description
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for the antioxidant, antifungal, cardiovascular, and antidiabetic therapeutic areas. The company was incorporated in 1984 and is headquartered in Mumbai, India.
Employees
1064
Investor relations
-
CEO
Country
India
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found